Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18935594 | 0.86 | CYP11B2 (0.40) | CYP11B2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL19633835 | 0.82 | CNR2 (0.35) | CNR1CNR2 | |
| SCHEMBL19592946 | 0.80 | CNR2 (0.38) | CYP11B2CNR1CNR2CHRNB2CHRNA4 | |
| SCHEMBL19251214 | 0.79 | CYP11B2 (0.37) | CYP11B2RAF1CYP11B1CYP1A2METAP2 | |
| SCHEMBL9967844 | 0.78 | KIF11 (0.44) | CYP11B2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL19274420 | 0.77 | CNR2 (0.33) | CNR1CNR2 | |
| SCHEMBL18516838 | 0.75 | CNR2 (0.36) | CYP11B2CNR1CNR2CHRNB2CHRNA4 | |
| SCHEMBL14822598 | 0.75 | CYP11B2 (0.55) | CYP11B2RAF1CYP11B1 | |
| SCHEMBL22338688 | 0.75 | CYP1A2 (0.40) | CYP11B2RAF1CYP11B1CYP1A2METAP2 | |
| SCHEMBL19040922 | 0.75 | CNR2 (0.53) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889571-B2 | Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias | Terns, Inc. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10858360-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20200087283-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. (US) | 2020-03-19 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087283-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | CYP11B2 3542/4885CNR1 4740/4885CNR2 4682/4885 |
| US-10858360-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | CYP11B2 450/4885CNR1 4239/4885CNR2 4524/4885 |
| US-10889571-B2 | Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias | ABL1, ABL2, BCR | CYP11B2 2094/4885CNR1 4256/4885CNR2 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.